High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery

Clinical trial NCT02203604 · TERMINATED

Trial details

NCT number: NCT02203604
Sponsor: CINJRegulatory
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Recurrent Melanoma Stage IIIA Melanoma Stage IIIB Melanoma Stage IIIC Melanoma Stage IV Melanoma

Start date: 2014-11-26
Primary completion: 2020-01-27
Enrollment: 9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.